Pharmacy

Image description

FDA approves first generic version of Nexium tabs

The Food and Drug Administration on Monday announced approval for the first generic version of Nexium (esomeprazole magnesium delayed-release capsules), which are used to treat gastroesophageal reflux disease in adults and children ages 1 year and older.

Image description

Meningococcal vaccine Bexsero gets FDA approval

The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.

 

Image description

FDA grants approval to Natpara

The Food and Drug Administration last week approved Natpara (parathyroid horomone), which is indicated to control low blood calcium levels in patients who have hypoparathyroidism.

 

Image description

Purdue Pharma launches Hysingla ER

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

Image description

Rx trends 2015: Treating the highest-cost patients

Some 10,000 Americans are turning 65 every day, swelling the Medicare rolls and increasing pressure on an already overstretched health system. Pharmacies are joining other health providers and insurers to help reduce costs of care for these newly minted seniors.

 

Image description

Camber launches generic Protonix

Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.

 

Image description

IBS market to reach $1.5 billion by 2023

The global therapeutics market for Irritable Bowel Syndrome is set to rise in value from $589.6 million in 2013 to $1.5 billion by 2023, representing a high compound annual growth rate of almost 9.9%, according to a report published Thursday by research and consulting firm GlobalData.